Abstract
Multidrug resistance (MDR), which is a significant impediment to the success of cancer chemotherapy, is attributable to various defensive mechanisms in cancer. Initially, overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp) was considered the most important mechanism for drug resistance; hence, many investigators for a long time focused on the development of specific ABC transporter inhibitors. However, to date their efforts have failed to develop a clinically applicable drug, leaving only a number of problems. The concept of cancer stem cells (CSCs) has provided new directions for both cancer and MDR research. MDR is known to be one of the most important features of CSCs and thus plays a crucial role in cancer recurrence and exacerbation. Therefore, in recent years, research targeting CSCs has been increasing rapidly in search of an effective cancer treatment. Here, we review the drugs that have been studied and developed to overcome MDR and CSCs, and discuss the limitations and future perspectives.
Introduction
Chemotherapy is one of the most effective treatments for cancer; however, its success has been challenged by the acquisition of multidrug resistance (MDR) (). MDR is caused by sustained (dose-dependent or time-dependent) administration of chemotherapeutic drugs, resulting in cross-resistance to a broad spectrum of structurally- and mechanically-distinct chemotherapeutic drugs (). There are several mechanisms underlying MDR (, ): (i) increased pumping out of the drug through efflux pumps such as P-glycoprotein (P-gp) encoded by ABCB1 (); (ii) decreased uptake of the drug through transporters; (iii) activation of drug-metabolizing enzymes such as cytochrome P450 and glutathione S-transferase; (iv) activation of DNA repair systems; (v) evasion of apoptosis. The first three of these processes are conducive to the development of resistance by preventing the drug from reaching an effective concentration, while the remaining two mechanisms achieve resistance by detoxifying the action of the drug. Based on the mechanisms described, we have been trying to establish strategies for overcoming MDR. Before discussing them further, we need to understand the existence of cancer stem cells (CSCs) and their roles in cancer biology. CSCs, also known as tumor-initiating cells (TICs), are a small population of cancer cells that have the ability to self-renew and differentiate similar to normal stem cells (NSCs). However, as CSCs are tumorigenic, they can contribute to the aggravation and recurrence of cancer (). According to a CSC model that explains the relationship between CSC and MDR, increased expression of ATP-binding cassette (ABC) transporters and other genes contributes to the intrinsic resistance of CSCs to chemotherapy (, ). CSCs have relatively slow cell-cycle kinetics and are therefore targeted less by chemotherapeutic drugs compared to rapidly dividing cells (). In addition to the well-known ABC transporters (, ), many other drug resistance mechanisms of CSCs have been identified, for example, aldehyde dehydrogenases (ALDHs) (), epithelial-mesenchymal transition (EMT) (), epigenetic modifications (, ), factors affecting tumor microenvironment, such as hypoxia (), and signaling pathways (ā). In this review, we provide a brief outline of MDR mechanisms and focus on the investigated drugs.
Current Strategies to Overcome MDR
Targeting ABC Transporters
ABC transporters including ABCB1, ABCC1, and ABCG2 are expressed in cancer stem/progenitor cells. These transporters have broad drug specificity and pump out a wide range of structurally- and mechanically-unrelated compounds, thereby lowering the intracellular accumulation of these compounds and consequently diminishing their biological efficacies (). Several chemotherapeutic agents in clinical use are susceptible to ABC transporter-mediated efflux, such as microtubule-targeting taxanes (e.g., docetaxel and paclitaxel) and vinca alkaloids (vinblastine and vincristine), DNA-damaging anthracyclines (daunorubicin and doxorubicin), topoisomerase inhibitors (etoposide and topotecan), and tyrosine kinase inhibitors (dasatinib and gefitinib) (). Therefore, developing strategies to target ABC transporters is an important area of cancer research, and many studies have been conducted accordingly (). There are three approaches: (i) regulating the function of ABC transporters using competitive or allosteric inhibitors (Table 1) as well as the antibodies that target ABC transporters, such as UIC2 and MRK16 (86); (ii) regulating gene expression of ABC transporters at the transcriptional or translational level because, as with trabectedin, it is an attractive strategy to control ABC transporters at the transcriptional level by affecting the MDR enhanceosome (87ā89); (iii) using anticancer drugs that are poor substrates of P-gp, such as ixabepilone (Table 1). Until ixabepilone was launched, efforts to develop drugs targeting ABC transporters had been a driving force in the development of first-, second-, and third-generation P-gp inhibitors (90, 91). However, it has been reported that first-generation inhibitors have low potency and high toxicity, and second-generation inhibitors have frequent drug-drug interactions (92). With the third-generation inhibitors, there have been many improvements with regard to the drawbacks of the previous generations, but clinical trial data are still insufficient. In effect, most clinical trials have been discontinued. Because NSCs, including hematopoietic stem cells, unrestricted somatic stem cells, and mesenchymal stem cells, also express ABC transporters to protect themselves from cytotoxic agents (93), inhibiting ABC transporters may cause serious side effects such as hematopoietic disorders due to bone marrow dysfunction. Therefore, the emergence of ixabepilone was inevitable and has been well-received. Like taxanes, ixabepilone leads to G2/M phase arrest by stabilizing microtubules and promoting tubulin polymerization. However, ixabepilone has a very important feature (not found in taxanes) effective against cancer cells that acquire MDR following repeated chemotherapy, as this drug is not pumped out through P-gp. Now, developing drugs that are not substrates of P-gp has become a trend for overcoming MDR cancer. In light of ixabepilone, chemical modifications of paclitaxel and vinblastine have also been attempted in succession, producing cabazitaxel and ortataxel, and vinflunine, respectively (Table 1). After these modifications, increased cytotoxic effects were observed in P-gp-overexpressing cell lines ().
Table 1
| Drugs | MOA | Clinical trial | References |
|---|---|---|---|
| ABC transporter inhibitors | |||
| Cyclosporine | 1st generation ABCB1 competitive inhibitors | ā | () |
| Nicardipine | () | ||
| Quinine | () | ||
| Tamoxifen | () | ||
| Verapamil | () | ||
| Cinchonine | 2nd generation ABCB1 competitive inhibitors | ā | () |
| Dexverapamil | () | ||
| Toremifene | () | ||
| Valspodar (PSC-833) | () | ||
| Biricodar (VX-710) | 2nd generation ABCB1 and ABCC1 competitive inhibitors | ā | () |
| Dofequidar (MS-209) | () | ||
| Laniquidar (R101933) | 3rd generation ABCB1 competitive inhibitors | ā | () |
| Lonafarnib (SCH66336) | () | ||
| Zosuquidar (LY335979) | () | ||
| Elacridar (GF120918) | 3rd generation ABCB1 and ABCG2 competitive inhibitors | ā | () |
| Tariquidar (XR9576) | () | ||
| Fumitremorgin C | ABCG2 competitive inhibitor | ā | () |
| Flupentixol | ABCB1 allosteric modulators | ā | () |
| Non-substrates of P-gp | |||
| Ixabepilone | Microtubule inhibitor | FDA approval | () |
| Cabazitaxel | () | ||
| Ortataxel | Phase 2 | () | |
| Vinflunine | Phase 3 | () | |
| ALDH1 inhibitors | |||
| Disulfiram | Copper-dependent proteasome inhibitor | Phase 2 | (, ) |
| Tretinoin | ā | ā | () |
| AMPK activators | |||
| Metformin | ā | Phase 2/3 | (, ) |
| Thalidezine | Autophagic cell death inducer | ā | () |
| VEGF inhibitor | |||
| Bevacizumab | Anti-VEGF antibody | FDA approval | () |
| RTK inhibitor | |||
| Sorafenib | Multikinase inhibitor | FDA approval | () |
| Vascular disrupting agents | |||
| Combretastatin A4 | Tubulin-binding agents | Phase 1/2 | () |
| Plocabulin | () | ||
| BET inhibitors | |||
| TEN-010 (JQ2) | ā | Phase 1 | () |
| CC-90010 | BRD2 inhibitor | Phase 1 | () |
| ABBV-744 | BRD4 inhibitors | Phase 1 | () |
| CPI-0610 | () | ||
| I-BET151 | BRD2 and BRD4 inhibitor | Phase 1 | () |
| OTX015 | BRD2, BRD3, and BRD4 inhibitor | Phase 1 | (, ) |
| ABBV-075 | BRD2, BRD3, BRD4, and BRDT inhibitors | Phase 1 | () |
| FT-1101 | () | ||
| I-BET762 | Phase 1/2 | () | |
| HDAC inhibitors | |||
| Vorinostat | Pan-HDAC inhibitors | FDA approval | (, ) |
| Panobinostat | () | ||
| KDM1 inhibitors | |||
| Tranylcypromine | Non-selective irreversible inhibitor | Phase 1/2 | () |
| GSK-2879552 | Selective irreversible inhibitors | Phase 1 | () |
| IMG-7289 (Bomedemstat) | Phase 1/2 | () | |
| INCB-059872 | () | ||
| ORY-1001 (Iadademstat) | () | ||
| CC-90011 | Selective reversible inhibitors | Phase 1 | () |
| SPā2577 (Seclidemstat) | Phase 1/2 | () | |
| Notch signaling inhibitors | |||
| DAPT | γ-secretase inhibitors | ā | (, ) |
| RO4929097 | Phase 2 | () | |
| Hh signaling inhibitors | |||
| Cyclopamine | Smo inhibitors | ā | (, ) |
| Sonidegib | FDA approval | (77) | |
| Vismodegib | (77) | ||
| Wnt/β-catenin signaling inhibitors | |||
| Ipafricept | FZD8-Fc | Phase 1 | (78) |
| Rosmantuzumab | Anti-RSPO antibody | (79) | |
| Vantictumab | Anti-FZD1, 2, 5, 7, and 8 antibody | (79, 80) | |
| Foxy-5 | Wnt5a-mimicking peptide | Phase 2 | (81) |
| ETC-159 | Porcupine inhibitors | Phase 1 | (82) |
| LGK974 | Phase 2 | (83) | |
| CWP232291 | β-catenin inhibitors | Phase 1 | (84) |
| PRI-724 | (85) | ||
Drugs that reverse chemoresistance via various mechanisms.
Targeting Aldehyde Dehydrogenases
ALDH plays an important role in the differentiation of stem cells by converting retinol into retinoic acid, as well as detoxifying the cells by converting aldehyde into carboxylic acid, and thus ALDH is considered a biomarker for stem cells (, 94). Several studies have shown that ALDH-1 is correlated with CSCs. Gefitinib, an EGFR inhibitor, is used for breast-, lung-, and other cancers. However, it has been confirmed that ALDH1A1-positive CSCs are more resistant to gefitinib than ALDH1A1-negative CSCs (95). ALDH-1 expression is mediated by high expression of Snail, which regulates metastasis as a transcription factor and subsequently causes CSCs to develop resistance to chemotherapy (96). To solve this problem, ALDH inhibitors, such as diethylaminobenzaldehyde, disulfiram, and tretinoin, have been proposed (Table 1). Bromodomain and extra-terminal (BET) inhibitors such as JQ1 have also been proposed due to their ability to suppress ALDH1A1 expression (97).
Targeting Epithelial-Mesenchymal Transition
EMT is a process by which epithelial cells become mesenchymal stem cells. In this process, epithelial cells lose cell polarity and cell-cell adhesion function but gain migratory and invasive functions (98, 99). In other words, EMT causes cancer cells to exhibit stem-like features such as tumorigenicity. EMT also promotes metastasis that occurs mainly due to reduced expression of E-cadherin, which itself is directly repressed by Snail (100). Because EMT plays a crucial role in chemoresistance of CSCs, strategies to inhibit this process can be effective. Some studies have shown that AMP-activated kinase (AMPK) induces apoptosis of cancer cells, inhibits TGF-β-induced EMT and, consequently, can reverse drug resistance (101). AMPK activators that have been proposed include metformin and thalidezine (Table 1). Although the data are still insufficient, these activators seem to have enough potential to overcome chemoresistance. It has also been proposed that histone deacetylase (HDAC) inhibitors suppress EMT and attenuate chemoresistance (102).
Targeting Epigenetic Modifications
Histone acetylation, one of the most common post-translational modifications, is closely associated with CSC chemoresistance. This process, in which lysine residues are acetylated, is tightly regulated by histone acetyltransferases (HATs) and HDACs. Bromodomains (BRD) of the BET family proteins read acetyl-lysine (Kac) residues on histones and regulate gene expression. BET family proteins recruit the positive transcriptional elongation factor (P-TEFb), resulting in a transcriptional cascade of oncogenes (). Thus, inhibition of BET binding to acetylated histones suppresses cell proliferation and induces apoptosis. JQ1 is a potent, highly specific, and Kac competitive inhibitor for BET family proteins (97). Because JQ1 has a short half-life, its derivatives and structurally similar forms are undergoing clinical trials (Table 1). On the other hand, HDACs, which are epigenetic erasers, induce stem-like features by promoting EMT. HDACs also affect hypoxia-inducible factors (HIFs) and NF-ĪŗB related to apoptosis (103, 104), which are components of the tumor microenvironment. HDAC inhibitors, including vorinostat (SAHA) and panobinostat, suppress EGFR expression and reverse EMT (Table 1). In addition, these drugs have been successfully used in combination with BET inhibitors. Such epigenetic combination therapy improves clinical efficacy by reducing Myc expression. Lysine-specific demethylase 1 (KDM1, also known as LSD1) modulates histone methylation, and demethylation of H3K9me2, H3K4me3, and H3K36me3 contributes to KDM1-mediated chemoresistance (105). Inhibition of KDM1 activity was initially observed in monoamine oxidase (MAO) inhibitors such as tranylcypromine, which was accompanied by suppression of the stem cell properties of CSCs in vivo (106). Based on their structure, several selective KDM1 inhibitors have been developed (Table 1). In addition, the activity of KDM1 can be regulated by HDAC inhibitors, as crosstalk exists between KDM1 and HDAC. KDM1 and HDAC1/2 form the CoREST complex, which is associated with silencing gene expression. As a result, combination therapy with KDM1 inhibitors and HDAC inhibitors has been expected to have synergistic effects and has often been evaluated. Recently, KDM1-HDAC dual inhibitors such as corin have been reported (107). BMI1 and EZH2, which induce epigenetic silencing as polycomb group (PcG) members, have been reported to be associated with chemoresistance (108, 109). Besides, tumor suppressor genes are silenced by hypermethylation of promoter regions of DNA, and thus, chemotherapy loses its efficacy against many cancers (110).
Targeting Microenvironment
The cellular microenvironment plays an important role in determining cellular behavior. NSCs and CSCs are generated, maintained, and regulated within this microenvironment. The tumor microenvironment (TME) creates a niche for itself that influences not only the proliferation and differentiation of CSCs but also the response to drugs (111). Although cancer-associated fibroblasts (CAFs) as well as inflammation and immune cells are components of the TME, we have to discuss the crucial role of hypoxia in the TME. Hypoxia signaling contributes to chemoresistance of CSCs by increasing the expression of ABC transporters and ALDH (, 112, 113). In solid tumors, hypoxic regions are necessarily present and lead to angiogenesis through HIF1A and VEGF (114, 115). However, tumor angiogenesis is sloppy; hence, drugs do not reach effective concentrations in hypoxic cells. Thus, VEGF inhibitors such as bevacizumab and receptor tyrosine kinase (RTK) inhibitors such as sorafenib can enhance chemosensitivity. Vascular disrupting agents (VDAs), including tubulin-binding agents such as combretastatin A4 and plocabulin, also enhance chemosensitivity by increasing vessel permeability (Table 1). Of course, we should be careful not to inject these agents prior to chemotherapy because it could impair the delivery of chemotherapeutic drugs by reducing blood supply.
Targeting Signaling Pathways
Signaling pathways control cell responses, particularly the self-renewal, differentiation, and survival of CSCs. Among them, the Notch, Hedgehog (Hh), and Wnt/β-catenin signaling pathways are responsible for drug resistance (116). Notch induces the expression of survivin, which is an anti-apoptotic gene that inhibits apoptosis. This signaling is suppressed by γ-secretase inhibitors (GSIs) such as DAPT and RO4929097, which block the second cleavage of Notch receptors and release of the Notch-IC fragment from the cell membrane (Table 1). Hh signaling is critical in embryogenesis and has been found in many cancers (, 117). This signaling induces the activation of Smo and Gli1, which are involved in the drug resistance caused by overexpression of P-gp and BCRP (118). Thus, Smo inhibitors such as cyclopamine, vismodegib, and sonidegib can suppress chemoresistance (Table 1). Wnt/β-catenin signaling activated by Frizzleds (FZDs) is also associated with drug resistance due to overexpression of P-gp, BCRP, and MRP (119). Besides, this pathway promotes cell cycling, inhibits apoptosis, and mediates DNA repair processes. Although it has been suggested that the Wnt/β-catenin signaling pathway is undruggable, strategies to target it have been explored because of their various therapeutic potential. Indeed, there has been an effort to develop drugs that inhibit Wnt/β-catenin signaling (Table 1).
Future Perspectives
To date, many chemotherapeutic drugs have been developed and many studies conducted to overcome MDR. The newer strategies that we have covered above have limitations, however, and so more work is needed with different approaches being explored to find effective and lasting treatment. Any strategy for overcoming MDR should not affect NCSs, but only CSCs. There are a few things to pay attention to for selective targeting of CSCs: (i) encapsulation of anticancer drugs in liposomes, micelles, and nanoparticles, i.e., nanotechnology-based drug delivery (120). The improvement of pharmacokinetic properties, tumor-specific delivery due to the enhanced permeability and retention (EPR) effect, and resistance to efflux pumps because of the size-exclusion effect are representative advantages of nanomaterials (NMs) (121ā123). Thus, NMs are expected to increase the therapeutic effect and reduce unwanted side effects of anticancer drugs. Moreover, dual drug-loaded NMs can lead to better therapeutic effects (124). For example, pluronics, which are amphiphilic polymers and form nano-sized micellar structures, have been increasingly regarded as CSC modulators (125, 126). Pluronics are not just drug delivery carriers; rather, they inhibit metastasis and activate apoptosis by mediating the release of cytochrome c and apoptosis inducing factor (AIF). In addition, they can alter the microenvironment and suppress CSCs effectively. At present, only SP1049C (doxorubicin with pluronics L61 and F127 micelles) is in phase 3 trials (127), but there are reasons to be optimistic. (ii) Targeting microRNAs (miRNAs), which mediate translational repression and mRNA degradation mainly by binding to the 3ā² UTR. Previous studies have shown that miRNAs regulate ABC transporters in CSCs (128, 129); for instance, miR-212, miR-328, miR-451, and so on. Some miRNAs, including miR-21 and miR-222, are oncogenic and up-regulated in cancer cells, while other miRNAs, including miR-15 and miR-181, are tumor suppressive and down-regulated in cancer cells (, 130). (iii) Targeting MDR mRNA (131, 132), through which antisense oligonucleotides (aODNs) are used to down-regulate the expression of specific genes. Small interfering RNAs (siRNAs) also silence specific genes because they are artificial double-stranded RNA (dsRNA) molecules with functions similar to those of miRNA. If they selectively target tumorigenic genes, cancer cells will become chemosensitive. There are no clinical data yet to suggest that MDR can be completely reversed using this RNA interference (RNAi) technology, but it is likely that drugs related to RNAi will be developed in the near future. (iv) Transferring MDR genes into NSCs, especially bone marrow stem cells (133ā135). Most chemotherapeutic drugs suppress the bone marrow and, as a result, blood cells such as erythrocytes, leukocytes, and thrombocytes do not function properly, and the ensuing loss of oxygen transport, immune response, and bleeding control functions causes serious adverse effects. To prevent these adverse effects, gene transfer technology has emerged, making it possible to administer high doses of chemotherapeutic drugs. In the transplantation model of CD34-positive peripheral blood stem cell (PBSC) infection with retroviral vectors containing MDR genes, long-term myeloprotection was achieved, demonstrating the safety of transplantation (136).
Conclusion
Over the past few decades there have been many strategies used to treat cancer, from conventional radiation therapy, chemotherapy to recent targeted therapy, and immunotherapy. It is no exaggeration to say that the flow of this change has been led by the discovery of various factors that cause MDR acquisition in cancer cells, especially ABC transporters. By discovering ABC transporters and identifying their functions, new possibilities have emerged for cancer treatment. Initially, many studies were focused on the direct inhibition of ABC transporters such as P-gp inhibitors. However, because they are less selective and less potent, differ in their in vitro and in vivo data, and often cause severe adverse effects, so far no drugs that directly target or inhibit P-gp have been accepted for clinical use. Although direct inhibition of ABC transporters may not be effective, the transporters remain attractive targets because enhanced drug efflux through the transporters is one of the most important causes of MDR acquisition. Therefore, rather than directly inhibiting the ABC transporters, it would be effective to devise alternative strategies to avoid drug efflux via transporters. The transporter-mediated MDR might be overcome by developing novel anticancer drugs with P-gp non-substrates. In addition, we have introduced alternative approaches for targeting CSCs that focus on ALDHs, EMT, epigenetic modifications, the microenvironment, and signaling pathways (Figure 1). We have also discussed the drugs being developed in each approach: (i) ABC transporter inhibitors and non-substrates; (ii) ALDH inhibitors; (iii) AMPK activators; (iv) BET inhibitors, HDAC inhibitors, and KDM1 inhibitors; (v) VEGF inhibitors, RTK inhibitors, and vascular disrupting agents; (vi) Notch inhibitors, Smo inhibitors, and Wnt/β-catenin inhibitors. One of the big obstacles we are facing now is whether we can selectively influence CSCs only. NSCs and CSCs share the same characteristics; therefore, solving this problem is a complex task. Although promising solutions have been proposed, more research should be conducted to support the arguments relating to nanotechnology-based drug delivery, RNAi technology, and gene transfer technology. It is worth noting that these approaches are directly or indirectly related to ABC transporters. It is hoped that all of the approaches reviewed here will help devise new strategies to overcome MDR and to eradicate MDR cancer.
Figure 1
Statements
Author contributions
YC and YK participated in manuscript drafting and revision of this article.
Funding
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) [NRF-2018R1A2B2005646 (to YK)].
Acknowledgments
We would like to thank Bokyeong Kim for providing the illustration used herein.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
ThomasHColeyHM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. (2003) 10:159ā65. 10.1177/107327480301000207
2.
AmbudkarSVKimchi-SarfatyCSaunaZEGottesmanMM. P-glycoprotein: from genomics to mechanism. Oncogene. (2003) 22:7468ā85. 10.1038/sj.onc.1206948
3.
MoitraK. Overcoming multidrug resistance in cancer stem cells. BioMed Res Int. (2015) 2015:635745ā8. 10.1155/2015/635745
4.
PanSTLiZLHeZXQiuJXZhouSF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. (2016) 43:723ā37. 10.1111/1440-1681.12581
5.
AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. (1999) 39:361ā98. 10.1146/annurev.pharmtox.39.1.361
6.
Hirschmann-JaxCFosterAEWulfGGNuchternJGJaxTWGobelUet al. A distinct āside populationā of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. (2004) 101:14228ā33. 10.1073/pnas.0400067101
7.
JungYKimW. Cancer stem cell targeting: are we there yet?Arch Pharm Res. (2015) 38:414ā22. 10.1007/s12272-015-0570-2
8.
MaLLaiDLiuTChengWGuoL. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). (2010) 42:593ā602. 10.1093/abbs/gmq067
9.
MooreNLyleS. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. (2011) 2011:396076. 10.1155/2011/396076
10.
GottesmanMMFojoTBatesSE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. (2002) 2:48ā58. 10.1038/nrc706
11.
RahaDWilsonTRPengJPetersonDYuePEvangelistaMet al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. (2014) 74:3579ā90. 10.1158/0008-5472.CAN-13-3456
12.
ShibueTWeinbergRA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. (2017) 14:611ā29. 10.1038/nrclinonc.2017.44
13.
WainwrightENScaffidiP. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer. (2017) 3:372ā86. 10.1016/j.trecan.2017.04.004
14.
MunozPIliouMSEstellerM. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol. (2012) 6:620ā36. 10.1016/j.molonc.2012.10.006
15.
BaoBAzmiASAliSAhmadALiYBanerjeeSet al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. (2012) 1826:272ā96. 10.1016/j.bbcan.2012.04.008
16.
DontuGJacksonKWMcNicholasEKawamuraMJAbdallahWMWichaMS. Role of Notch signaling in cell fate determination of human mammary stemprogenitor cells. Breast Cancer Res. (2004) 6:R605ā15. 10.1186/bcr920
17.
YangLXieGFanQXieJ. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene. (2010) 29:469ā81. 10.1038/onc.2009.392
18.
YangWYanHXChenLLiuQHeYQYuLXet al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. (2008) 68:4287ā95. 10.1158/0008-5472.CAN-07-6691
19.
WuCPCalcagnoAMAmbudkarSV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. (2008) 1:93ā105. 10.2174/1874467210801020093
20.
KrishnaRMayerLD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. (2000) 11:265ā83. 10.1016/s0928-0987(00)00114-7
21.
ChungFSSantiagoJSJesusMFTrinidadCVSeeMF. Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?Am J Cancer Res. (2016) 6:1583ā98.
22.
ChaoNJAiharaMBlumeKGSikicBI. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp Hematol. (1990) 18:1193ā8.
23.
JinYBinZQQiangHLiangCHuaCJunDet al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. (2009) 135:1369ā76. 10.1007/s00432-009-0578-4
24.
SolaryEVelayIChauffertBBidanJCaillotDDumasMet al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer. (1991) 68:1714ā9. 10.1002/1097-0142(19911015)68:8<1714::AID-CNCR2820680811>3.0.CO;2-2
25.
LiCKimMChoiHChoiJ. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res. (2011) 34:1965ā72. 10.1007/s12272-011-1117-9
26.
SpoelstraECWesterhoffHVPinedoHMDekkerHLankelmaJ. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem. (1994) 221:363ā73. 10.1111/j.1432-1033.1994.tb18748.x
27.
SolaryEMannoneLMoreauDCaillotDCasasnovasROGuyHet al. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia. (2000) 14:2085ā94. 10.1038/sj.leu.2401945
28.
WilsonWHJamis-DowCBryantGBalisFMKleckerRWBatesSEet al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol. (1995) 13:1985ā94. 10.1200/JCO.1995.13.8.1985
29.
MubasharMHarringtonKJChaudharyKSLalaniEStampGWPetersAM. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Acta Oncol. (2004) 43:443ā52. 10.1080/02841860410031048
30.
TwentymanPRBleehenNM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer. (1991) 27:1639ā42. 10.1016/0277-5379(91)90435-G
31.
GandhiLHardingMWNeubauerMLangerCJMooreMRossHJet al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. (2007) 109:924ā32. 10.1002/cncr.22492
32.
NakanishiOBabaMSaitoAYamashitaTSatoWAbeHet al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res. (1997) 9:61ā9.
33.
van ZuylenLSparreboomAvan der GaastANooterKEskensFABrouwerEet al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer. (2002) 38:1090ā9. 10.1016/S0959-8049(02)00035-7
34.
ShiBYaremkoBHajianGTerracinaGBishopWRLiuMet al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. (2000) 46:387ā93. 10.1007/s002800000170
35.
GreenLJMarderPSlapakCA. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol. (2001) 61:1393ā9. 10.1016/S0006-2952(01)00599-8
36.
de BruinMMiyakeKLitmanTRobeyRBatesSE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. (1999) 146:117ā26. 10.1016/S0304-3835(99)00182-2
37.
LusvarghiSAmbudkarSV. ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators. Biochem J. (2019) 476:3737ā50. 10.1042/BCJ20190736
38.
RabindranSKHeHSinghMBrownECollinsKIAnnableTet al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. (1998) 58:5850ā8.
39.
GhoshPMoitraKMakiNDeyS. Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates. Arch Biochem Biophys. (2006) 450:100ā12. 10.1016/j.abb.2006.02.025
40.
FornierMN. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer. (2007) 7:9ā15. 10.3816/CBC.2007.n.036
41.
Di NunnoVMollicaVMassariF. Cabazitaxel in metastatic prostate cancer. N Engl J Med. (2020) 382:1286. 10.1056/NEJMc2000990
42.
BrooksTAMindermanHO'LoughlinKLPeraPOjimaIBaerMRet al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. (2003) 2:1195ā205.
43.
WaghrayDZhangQ. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem. (2018) 61:5108ā21. 10.1021/acs.jmedchem.7b01457
44.
MacDonaghLGallagherMFFfrenchBGaschCBreenEGraySGet al. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. Oncotarget. (2017) 8:72544ā63. 10.18632/oncotarget.19881
45.
Toledo-GuzmanMEHernandezMIGomez-GallegosAAOrtiz-SanchezE. ALDH as a stem cell marker in solid tumors. Curr Stem Cell Res Ther. (2019) 14:375ā88. 10.2174/1574888X13666180810120012
46.
MorebJSUcar-BilyeuDAKhanA. Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells. Cancer Chemother Pharmacol. (2017) 79:295ā301. 10.1007/s00280-016-3213-5
47.
ChoiYKParkKG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. (2013) 36:279ā87. 10.1007/s10059-013-0169-8
48.
QuCQuCZhangWZhangWZhengGZhengGet al. Metformin reverses multidrug resistance and epithelialāmesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem. (2014) 386:63ā71. 10.1007/s11010-013-1845-x
49.
LawBYKGordillo-MartĆnezFQuYQZhangNXuSWCoghiPSet al. Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death. Oncotarget. (2017) 8:30077ā91. 10.18632/oncotarget.15616
50.
HeijmenLTer VoertEGPuntCJHeerschapAOyenWJBussinkJet al. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging. (2014) 9:237ā45. 10.1002/cmmi.1564
51.
QiuYShanWYangYJinMDaiYYangHet al. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α. Cell Death Discov. (2019) 5:120. 10.1038/s41420-019-0200-8
52.
CloseA. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Future Med Chem. (2016) 8:443ā62. 10.4155/fmc.16.6
53.
HorsmanMRSiemannDW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. (2006) 66:11520ā39. 10.1158/0008-5472.CAN-06-2848
54.
AlqahtaniAChoucairKAshrafMHammoudaDMAlloghbiAKhanTet al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. (2019) 5:FSO372. 10.4155/fsoa-2018-0115
55.
BoldenJETasdemirNDowLEvan EsJHWilkinsonJEZhaoZet al. Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. Cell Rep. (2014) 8:1919ā29. 10.1016/j.celrep.2014.08.025
56.
SiuKTRamachandranJYeeAJEdaHSantoLPanaroniCet al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. (2017) 31:1760ā9. 10.1038/leu.2016.355
57.
LongJLiBRodriguez-BlancoJPastoriCVolmarCWahlestedtCet al. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. (2014) 289:35494ā502. 10.1074/jbc.M114.595348
58.
CoudeMMBraunTBerrouJDupontMBertrandSMasseAet al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. (2015) 6:17698ā712. 10.18632/oncotarget.4131
59.
BoiMGaudioEBonettiPKweeIBernasconiETarantelliCet al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. (2015) 21:1628ā38. 10.1158/1078-0432.CCR-14-1561
60.
BuiMHLinXAlbertDHLiLLamLTFaivreEJet al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. (2017) 77:2976ā89. 10.1158/0008-5472.CAN-16-1793
61.
ZhangDLealASCarapellucciSZydeckKSpornMBLibyKT. Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762. Cancer Prev Res. (2018) 11:143ā56. 10.1158/1940-6207.CAPR-17-0264
62.
BruzzeseFLeoneARoccoMCarboneCPiroGCaragliaMet al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. (2011) 226:2378ā90. 10.1002/jcp.22574
63.
Di CostanzoADel GaudioNMigliaccioAAltucciL. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol. (2014) 88:1651ā68. 10.1007/s00204-014-1315-6
64.
LingYLiuJQianJMengCGuoJGaoWet al. Recent advances in multi-target drugs targeting protein kinases and histone deacetylases in cancer therapy. Curr Med Chem. (2020). 10.2174/0929867327666200102115720. [Epub ahead of print].
65.
BindaCValenteSRomanenghiMPilottoSCirilliRKarytinosAet al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc. (2010) 132:6827ā33. 10.1021/ja101557k
66.
MohammadHPSmithemanKNKamatCDSoongDFederowiczKEVan AllerGSet al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. (2015) 28:57ā69. 10.1016/j.ccell.2015.06.002
67.
FuXZhangPYuB. Advances toward LSD1 inhibitors for cancer therapy. Future Med Chem. (2017) 9:1227ā42. 10.4155/fmc-2017-0068
68.
ShawHVKovalAKatanaevVL. Targeting the Wnt signalling pathway in cancer: prospects and perils. Swiss Med Wkly. (2019) 149:w20129. 10.4414/smw.2019.20129
69.
MaesTMascaroCTirapuIEstiarteACiceriFLunardiSet al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. (2018) 33:495ā511.e12. 10.1016/j.ccell.2018.02.002
70.
HollebecqueAde BonoJSPlummerRIsambertNMartin-RomanoPBaudinEet al. Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Ann Oncol. (2019) 29(Suppl. 8):viii649ā69. 10.1093/annonc/mdy303
71.
RaffaellaSoldiTithiGhosh HalderAlexisWestonTrasonThodeKevinDrennerRhondaLewiset al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. bioRxiv.10.1101/2020.01.10.902528
72.
YoungMJWuYHChiuWTWengTYHuangYFChouCY. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells. Carcinogenesis. (2015) 36:498ā507. 10.1093/carcin/bgv018
73.
MengRDSheltonCCLiYQinLNottermanDPatyPBet al. gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. (2009) 69:573ā82. 10.1158/0008-5472.CAN-08-2088
74.
LeeSMMoonJRedmanBGChidiacTFlahertyLEZhaYet al. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. (2015) 121:432ā40. 10.1002/cncr.29055
75.
SongZYueWWeiBWangNLiTGuanLet al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS ONE. (2011) 6:e17687. 10.1371/journal.pone.0017687
76.
DirixL. Discovery and exploitation of novel targets by approved drugs. J Clin Oncol. (2014) 32:720ā1. 10.1200/JCO.2013.53.7118
77.
DummerRAsciertoPABasset-SeguinNDrenoBGarbeCGutzmerRet al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. (2020). 10.1111/jdv.16230. [Epub ahead of print].
78.
JimenoAGordonMChughRMessersmithWMendelsonDDupontJet al. A first-in-human phase I study of the anticancer stem cell agent Ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res. (2017) 23:7490ā7. 10.1158/1078-0432.CCR-17-2157
79.
KatohMKatohM. Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int J Mol Med. (2017) 40:587ā606. 10.3892/ijmm.2017.3071
80.
KatohM. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. (2017) 51:1357ā69. 10.3892/ijo.2017.4129
81.
SafholmALeanderssonKDejmekJNielsenCKVilloutreixBOAnderssonT. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem. (2006) 281:2740ā9. 10.1074/jbc.M508386200
82.
MadanBKeZHarmstonNHoSYFroisAOAlamJet al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. (2016) 35:2197ā207. 10.1038/onc.2015.280
83.
LiuJPanSHsiehMHNgNSunFWangTet al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci USA. (2013) 110:20224ā9. 10.1073/pnas.1314239110
84.
PakSParkSKimYParkJHParkCHLeeKJet al. Correction to: the small molecule WNT/beta-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. J Exp Clin Cancer Res. (2019) 38:440ā1. 10.1186/s13046-019-1451-1
85.
GangEJHsiehYTPhamJZhaoYNguyenCHuantesSet al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. (2014) 33:2169ā78. 10.1038/onc.2013.169
86.
RitchieTKKwonHAtkinsWM. Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. J Biol Chem. (2011) 286:39489ā96. 10.1074/jbc.M111.284554
87.
ScottoKWJohnsonRA. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv. (2001) 1:117ā25.
88.
ScottoKW. Transcriptional regulation of ABC drug transporters. Oncogene. (2003) 22:7496ā511. 10.1038/sj.onc.1206950
89.
SouidSAissaouiDSrairi-AbidNEssafi-BenkhadirK. Trabectedin (yondelisĀ®) as a therapeutic option in gynecological cancers: a focus on its mechanisms of action, clinical activity, and genomic predictors of drug response. Curr Drug Targets. (2020) 21. 10.2174/1389450121666200128161733. [Epub ahead of print].
90.
SzakacsGPatersonJKLudwigJABooth-GentheCGottesmanMM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. (2006) 5:219ā34. 10.1038/nrd1984
91.
PalmeiraASousaEVasconcelosMHPintoMM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. (2012) 19:1946ā2025. 10.2174/092986712800167392
92.
AminML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. (2013) 7:27ā34. 10.4137/DTI.S12519
93.
ShackletonM. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. (2010) 20:85ā92. 10.1016/j.semcancer.2010.04.002
94.
ChuteJPMuramotoGGWhitesidesJColvinMSafiRChaoNJet al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA. (2006) 103:11707ā12. 10.1073/pnas.0603806103
95.
HuangCPTsaiMFChangTHTangWCChenSYLaiHHet al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. (2013) 328:144ā51. 10.1016/j.canlet.2012.08.021
96.
ZhouWLvRQiWWuDXuYLiuW. Snail contributes to the maintenance of stem cell like phenotype cells in human pancreatic cancer. PLoS ONE. (2014) 9:e87409. 10.1371/journal.pone.0087409
97.
YokoyamaYZhuHLeeJHKossenkovAVWuSYWickramasingheJMet al. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Res. (2016) 76:6320ā30. 10.1158/0008-5472.CAN-16-0854
98.
Celia-TerrassaTJollyMK. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb Perspect Med. (2019) a036905. 10.1101/cshperspect.a036905. [Epub ahead of print].
99.
OskarssonTBatlleEMassagueJ. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. (2014) 14:306ā21. 10.1016/j.stem.2014.02.002
100.
PuisieuxABrabletzTCaramelJ. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. (2014) 16:488ā94. 10.1038/ncb2976
101.
LinHLiNHeHYingYSunkaraSLuoLet al. AMPK inhibits the stimulatory effects of TGF-beta on Smad2/3 activity, cell migration, and epithelial-to-mesenchymal transition. Mol Pharmacol. (2015) 88:1062ā71. 10.1124/mol.115.099549
102.
SakamotoTKobayashiSYamadaDNaganoHTomokuniATomimaruYet al. A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer. PLoS ONE. (2016) 11:e0145985. 10.1371/journal.pone.0145985
103.
HwangJWChoHLeeJYJeonYKimSNLeeSJet al. The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-kappaB and PPARgamma in multidrug-resistant cancer cells. Food Chem Toxicol. (2016) 96:35ā42. 10.1016/j.fct.2016.07.020
104.
BaudVKarinM. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. (2009) 8:33ā40. 10.1038/nrd2781
105.
McDonaldOGWuHTimpWDoiAFeinbergAP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. (2011) 18:867ā74. 10.1038/nsmb.2084
106.
ThinnesCCEnglandKSKawamuraAChowdhuryRSchofieldCJHopkinsonRJ. Targeting histone lysine demethylases - progress, challenges, and the future. Biochim Biophys Acta. (2014) 1839:1416ā32. 10.1016/j.bbagrm.2014.05.009
107.
KalinJHWuMGomezAVSongYDasJHaywardDet al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. (2018) 9:53ā4. 10.1038/s41467-017-02242-4
108.
CreaFDanesiRFarrarWL. Cancer stem cell epigenetics and chemoresistance. Epigenomics. (2009) 1:63ā79. 10.2217/epi.09.4
109.
PietersenAMHorlingsHMHauptmannMLangerodAAjouaouACornelissen-SteijgerPet al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. (2008) 10:R109. 10.1186/bcr2214
110.
Ibanez de CaceresICortes-SempereMMoratillaCMachado-PinillaRRodriguez-FanjulVManguan-GarciaCet al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. (2010) 29:1681ā90. 10.1038/onc.2009.454
111.
LauEYHoNPLeeTK. Cancer stem cells and their microenvironment: biology and therapeutic implications. Stem Cells Int. (2017) 2017:3714190. 10.1155/2017/3714190
112.
SeoEJKimDKJangIHChoiEJShinSHLeeSIet al. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. (2016) 7:55624ā38. 10.18632/oncotarget.10954
113.
GarsonKVanderhydenBC. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction. (2015) 149:59. 10.1530/REP-14-0234
114.
HajizadehFOkoyeIEsmailyMGhasemi ChaleshtariMMasjediAAziziGet al. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. Life Sci. (2019) 237:116952. 10.1016/j.lfs.2019.116952
115.
JingXYangFShaoCWeiKXieMShenHet al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. (2019) 18:157ā9. 10.1186/s12943-019-1089-9
116.
TakebeNMieleLHarrisPJJeongWBandoHKahnMet al. Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. (2015) 12:445ā64. 10.1038/nrclinonc.2015.61
117.
TangSNFuJNallDRodovaMShankarSSrivastavaRK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. (2012) 131:30ā40. 10.1002/ijc.26323
118.
Sims-MourtadaJIzzoJGAjaniJChaoKS. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. (2007) 26:5674ā9. 10.1038/sj.onc.1210356
119.
FlahautMMeierRCoulonANardouKANiggliFKMartinetDet al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene. (2009) 28:2245ā56. 10.1038/onc.2009.80
120.
ZhangMLiuECuiYHuangY. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol Med. (2017) 14:212ā27. 10.20892/j.issn.2095-3941.2017.0054
121.
GaoZZhangLSunY. Nanotechnology applied to overcome tumor drug resistance. J Control Release. (2012) 162:45ā55. 10.1016/j.jconrel.2012.05.051
122.
SteichenSDCaldorera-MooreMPeppasNA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. (2013) 48:416ā27. 10.1016/j.ejps.2012.12.006
123.
RempeRCramerSQiaoRGallaHJ. Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties. Cell Tissue Res. (2014) 355:717ā26. 10.1007/s00441-014-1819-7
124.
MaLKohliMSmithA. Nanoparticles for combination drug therapy. ACS Nano. (2013) 7:9518ā25. 10.1021/nn405674m
125.
KabanovAVBatrakovaEVAlakhovVY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. (2002) 54:759ā79. 10.1016/S0169-409X(02)00047-9
126.
DehghankelishadiPDorkooshF. Pluronic based nano-delivery systems; Prospective warrior in war against cancer. Nanomed Res J. (2016) 1:1ā7. 10.7508/nmrj.2016.01.001
127.
AlakhovaDYZhaoYLiSKabanovAV. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS ONE. (2013) 8:e72238. 10.1371/journal.pone.0072238
128.
DeSanoJTXuL. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. (2009) 11:682ā92. 10.1208/s12248-009-9147-7
129.
XingFWuKWatabeK. MicroRNAs in cancer stem cells: new regulators of stemness. Curr Pharm Des. (2014) 20:5319ā27. 10.2174/1381612820666140128210912
130.
LiangZWuHXiaJLiYZhangYHuangKet al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. (2010) 79:817ā24. 10.1016/j.bcp.2009.10.017
131.
ZouSCaoNChengDZhengRWangJZhuKet al. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int J Nanomed. (2012) 7:3823ā35. 10.2147/IJN.S29328
132.
XiongXLavasanifarA. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. (2011) 5:5202ā13. 10.1021/nn2013707
133.
Budak-AlpdoganTBanerjeeDBertinoJR. Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Ther. (2005) 12:849ā63. 10.1038/sj.cgt.7700866
134.
ZaboikinMSrinivasakumarNSchueningF. Gene therapy with drug resistance genes. Cancer Gene Ther. (2006) 13:335ā45. 10.1038/sj.cgt.7700912
135.
BertinoJR. Transfer of drug resistance genes into hematopoietic stem cells for marrow protection. Oncologist. (2008) 13:1036ā42. 10.1634/theoncologist.2008-0173
136.
O'ShaughnessyJACowanKHNienhuisAWMcDonaghKTSorrentinoBPDunbarCEet al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther. (1994) 5:891ā911. 10.1089/hum.1994.5.7-891
Summary
Keywords
multidrug resistance, ABC transporters, P-glycoprotein, cancer stem cells, epigenetics
Citation
Cho Y and Kim YK (2020) Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Front. Oncol. 10:764. doi: 10.3389/fonc.2020.00764
Received
10 March 2020
Accepted
21 April 2020
Published
02 June 2020
Volume
10 - 2020
Edited by
Sungpil Yoon, Sungkyunkwan University, South Korea
Reviewed by
Hyung Sik Kim, Sungkyunkwan University, South Korea; Xiaoju Wang, University of Michigan, United States
Updates
Copyright
Ā© 2020 Cho and Kim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yong Kee Kim yksnbk@sookmyung.ac.kr
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.